Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

English version České info

Background:
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB.

Methods and Findings:
Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1–6.0]), ofloxacin (aOR: 2.5 [1.6–3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3–2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3–3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7–4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7–4.3]), ofloxacin (aOR: 2.3 [1.3–3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4–2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9–3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4–6.0]).

Conclusions:
In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment.

Please see later in the article for the Editors' Summary.

Vyšlo v časopise: Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Med 9(8): e32767. doi:10.1371/journal.pmed.1001300
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001300

Souhrn

Zdroje

1. World Health Organization (2008) Guidelines for the programmatic management of drug resistant tuberculosis - emergency update. World Health Organization 247 p.

2. CamineroJA, SotgiuG, ZumlaA, MiglioriGB (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet 10: 621–629.

3. Akcakir Y (2010) Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis [PhD dissertation]. Montreal: Department of Epidemiology & Biostatistics, McGill University. 110 p.

4. OrensteinEW, BasuS, ShahNS, AndrewsJR, FriedlandGH, et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis:systematic review and meta-analysis. Lancet Infect Dis 9: 153–161.

5. JohnstonJC, ShahidiNC, SadatsafaviM, FitzGeraldJM (2009) Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4: e6914 doi:10.1371/journal.pone.0006914.

6. StewartLA, TierneyJF (2008) Clarke M on behalf of the Cochrane Individual Patient Data Meta-analysis Methods Group (2008) Reviews of individual patient data. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic reviews of Intervention. Wiley-Blackwell 548–558.

7. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva: World Health Organization. Available: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf.

8. World Health Organization (2006) Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 81: 430–432.

9. LasersonKF, ThorpeLE, LeimaneV, WeyerK, MitnickCD, et al. (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 640–645.

10. Schabenberger O (2011) Introducing the GLIMMIX Procedure for Generalized Linear Mixed Models. Available: http://www2.sas.com/proceedings/sugi30/196-30.pdf. Accessed 10 September 2010.

11. ThompsonSG, TurnerRM, WarnDE (2001) Multilevel models for meta-analysis, and their application to absolute risk difference. Stat Methods 10: 375–392.

12. TurnerRM, OmarRZ, YangM, GoldsteinH, ThompsonSG (2000) A Multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 19: 3417–3432.

13. HigginsJP, ThompsonSG (2002) Quantifying heterogeneity in meta-analysis. Stat Med 21: 1539–1558.

14. PinheiroJ, BatesDM (1995) Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Computational Graphical Satistics 4: 12–35.

15. Yarandi HN (2011) Handling missing data with multiple imputation using PROC MI in SAS. Available: http://analytics.ncsu.edu/sesug/2002/ST14.pdf. Accessed 1 February 2011.

16. AvendanoM, GoldsteinRS (2000) Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 7: 383–389.

17. BurgosM, GonzalezLC, PazEA, GournisE, PazA, et al. (2005) Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 40: 968–975.

18. IsemanMD, MadsenL, GobleM, PomerantzM (1990) Surgical intervention in the treatment of pulmonary disease caused by drug-resistant mycobacterium tuberculosis. Am Rev Respir Dis 141: 623–625.

19. ChanED, LaurelV, StrandMJ, ChanJF, HuynhMLN, et al. (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 169: 1103–1109.

20. ChiangCY, EnarsonDA, YuMC, BaiKJ, HuangRM, et al. (2006) Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 28: 980–985.

21. CoxHS, StobdanK, AllamuratovaS, SizaireV, TigayZN, et al. (2007) Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2: e1126 doi:10.1371/journal.pone.0001126.

22. DeRiemerK, Garcia-GarciaL, Bodadilla-del-ValleM, Palacinos-MartinezM, Martinez-GamboaA, et al. (2005) Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365: 1239–1345.

23. EscuderoE, PenaJM, Alvarez-SalaR, VazquezJJ, OrtegaA (2006) Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis 10: 409–414.

24. GeerligsWA, van AltenaR, delangeWCM, van SoolingenD, van der WerfTS (2000) Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 4: 758–764.

25. GranichRM, OhP, LewisB, PorcoTC, FloodJ (2005) Multidrug resistance among persons with tuberculosis in California, 1994–2003. JAMA 293: 2732–2739.

26. BanerjeeR, AllenJ, WestenhouseJ, OhP, ElmsW, et al. (2008) Extensively drug-resistant tuberculosis in California, 1993–2006. Clin Infect Dis 47: 450–457.

27. HoltzTH, LancasterJ, LasersonKF, WellsCD, ThorpeL, et al. (2006) Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999–2001. Int J Tuberc Lung Dis 10: 649–655.

28. KimDH, KimHJ, ParkSK, KongS, KimYS, et al. (2008) Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 178: 1075–1082.

29. KimHR, HwangSS, KimHJ, LeeSM, YooCG, et al. (2007) Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 45: 1290–1295.

30. KwonYS, KimYH, SuhGY, ChungM, KimH, et al. (2008) Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 47: 496–502.

31. RiekstinaV, LeimaneV, HoltzTH, LeimansJ, WellsCD (2007) Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc Lung Dis 11: 585–587.

32. LeimaneV, RiekstinaV, HoltzTH, ZarovskaE, SkripconokaV, et al. (2005) Clinical outcome of individualised treatment of multi-drugresistant tuberculosis in Latvia: a retrospective cohort study. Lancet 386: 318–326.

33. HoltzTH, StenbergM, KammererS, LasersonKF, RiekstinaV, et al. (2006) Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144: 650–659.

34. LockmanS, KruunerA, BinkinN, LevinaK, WangYC, et al. (2001) Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis 32: 373–80.

35. MasjediMR, TabarsiP, ChitsazP, BaghaeiP, MiraeidiM, et al. (2008) Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002–2006. Int J Tuberc Lung Dis 12: 750–755.

36. MiglioriGB, EspinalM, DanilovaID, PungaVV, GrzemskaM, et al. (2002) Frequency of recurrence among MDR-TB cases ‘successfully’ treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 6: 858–864.

37. MiglioriGB, BesozziG, GirardiE, KliimanK, LangeC, et al. (2007) Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 30: 623–626.

38. MitnickC, BayonaJ, PalaciosE, ShinSS, FurinJ, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348: 119–128.

39. MitnickC, ShinSS, SeungKJ, RichML, AtwoodSS, et al. (2010) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359: 563–574.

40. MunsiffSS, AhujaSD, LiJ, DriverCR (2006) Public-private collaboration for multidrug-resistant tuberculosis control in New York city. Int J Tuberc Lung Dis 10: 639–648.

41. LiJ, BurzynskiJN, LeeYA, BergD, DriverCR, et al. (2004) Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 126: 1770–1776.

42. NaritaM, AlonsoP, LazardoM, HollenderE, PitchenikA, et al. (2001) Treatment experience of multidrug-resistant tuberculosis in Florida, 1994–1997. Chest 120: 343–348.

43. O'RiordanP, SchwabU, LoganS, CookeG, WilkinsonRJ, et al. (2008) Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multidrug-resistant tuberculosis: case control study. PLoS One 3: e3173 doi:10.1371/journal.pone.0003173.

44. PalmeroDJ, AmbroggiM, BreaA, De LucasM, FulgenziA, et al. (2004) Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 8: 778–784.

45. ParkSK, LeeWC, LeeDH, MitnickCD, HanL, et al. (2004) Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 8: 361–368.

46. Pérez-GuzmánC, VargasMH, Martinez-RossierLA, Torres-CruzA, Villarreal-VelardeH (2002) Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 6: 1102–1109.

47. QuyHT, CobelensFGJ, LanNTN, BuuTN, LambregtsCSB, et al. (2006) Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 10: 45–51.

48. SchaafHS, SheanK, DonaldPR (2003) Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 88: 1106–1111.

49. ShinSS, PasechnikovAD, GelmanovaIY, PeremitinGG, StrelisAK, et al. (2006) Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 10: 402–408.

50. ShiraishiY, NakalimaY, KatsuragiN, KuraiM, TakahashiN (2004) Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 128: 523–528.

51. TupasiTE, QuelapioMID, OrillazaRB, AlcantaraC, MiraNRC, et al. (2003) DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed. Tuberculosis 83: 52–58.

52. TupasiTE, GuptaR, QuelapioMID, OrillazaRB, MiraNR, et al. (2006) Feasibility and cost-effectiveness of treating multidrug resistant tuberculosis: a cohort study in the Philippines. PLoS Med 3: e352 doi:10.1371/journal.pmed.0030352.

53. UffrediML, Truffot-PernotC, DautzenbergB, RenardM, JarlierV, et al. (2007) An intervention programme for the management of multidrug-resistant tuberculosis in France. Intl J Antimicrob Agents 29: 434–439.

54. Van DeunA, SalimMAH, DasAPK, BastianI, PortaelsF (2004) Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 8: 560–567.

55. Van DeunA, MaugAKJ, SalimMAH, DasPK, SarkerMR, et al. (2010) Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 684–692.

56. YewWW, ChanCK, LeungCC, ChauCH, TamCM, et al. (2003) Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis. Chest 124: 1476–1481.

57. YewWW, ChanCK, ChauCH, TamCM, LeungCC, et al. (2000) Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117: 744–751.

58. EspinalMA, KimSJ, SuarezPG, KamKM, KhomenkoAG, et al. (2000) Standard short-course chemotherapy for drug-resistance tuberculosis- treatment outcomes in 6 countries. JAMA 283: 2537–2545.

59. PsatyBM, SiscovickDS (2010) Minimizing bias due to confounding by indication in comparative effectiveness research the importance of restriction. JAMA 304: 897–898.

60. MitnickCD, CastroKG, HarringtonM, SacksLV, BurmanW (2007) Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 4: e292 doi:10.1371/journal.pmed.0040292.